A federal court ordered a Texas-based company to stop producing compounded drug products intended to be sterile until the company complies with the Federal Food, Drug, and Cosmetic Act (FD&C Act).
Federal court enters consent decree against Texas compounder, Pharm D Solutions, LLC to cease the manufacturing of drugs intended to be sterile due to insanitary conditions
More from FDA News AlertsMore posts in FDA News Alerts »
- Eli Lilly and Company Issues Voluntary Nationwide Recall of One Lot of GLUCAGON® Emergency Kit Due to Loss of Potency
- FDA Takes Steps Aimed at Improving Quality, Safety and Efficacy of Sunscreens
- Armstrong Medical Limited Recalls AMSORB PLUS PREFILLED G-CAN 1.0L Due to Reduced Gas Flow to Patients During Anesthesia
- FDA In Brief: FDA Publishes Material Safety Data to Promote Safer, More Effective Medical Devices